# AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-19 19:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Intelligence Brief
"AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial" developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by Investing News Network, Yahoo Finance, MedPage Today and grafa.com. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Key People, Organizations & Locations
AbbVie, Crohn, Skyrizi

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Investing News Network | AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn's Disease | 2026-10-19 09:15 | [Source Link](https://news.google.com/rss/articles/CBMixwJBVV95cUxQU2swRzZiNnd5dGcxM0pHQkQ0LUV4NnREZ3REb0xfMWdqWnJKY2hRSU5lMlpuMEZmYWdkdzFXY3EzQmR6QzI5NnZIcWo2MkNLa0hWWEo2MlNLUVRvUmdGeGI5a3pDVFdqOWUwdVdhRnFBRUJ3UE9oNHF5WWp1NXozRWpsVlltYVRsNzIybTVXU2RDdEtCaU5xRTJmSERTRGt2WTU3ZDY1Ujc4TlpMQ3VZZHJ4OW5YNGJTUnIxTFd2YVFZMVh1ZFZNRVViSVVxbDFBOVBUZTkxaUtqUmNiY3I4cGFoUlZ2Si1jdGU3ZEE2dUFGMXE2bEw5bWJPb184U0hES1dXckI0YXEzMF9Oa21CVkJTNkJuN01VMlZzSG9HdG5oWDRGMXBqZ1dOZy0yenNibUNYaHpxNVlhcmZvNzNwbFVFUEFsbFk?oc=5) |
| Yahoo Finance | SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 | 2026-10-19 09:15 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZWdwOTZlYS13c3B0TTlfb09IbmZWZ3FWNVNpRktLV1JuYVVlTEMtTEY0YXZ3QlV3eWd4TFZOOGFMS2xzNC1mOEdRUGxMQm9HUk9weXM5Mld2UFRBeWRfZDRWRFVMSWVZZUFuZTZXdlhYSllqaXgwVDhCd1YteUstRk5wb192RVRscFRIZzQ1ZUtjZHJ6T0I3VFZDMi1WMWtwdGtVem1ucDlXZw?oc=5) |
| MedPage Today | Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease | 2026-10-19 09:15 | [Source Link](https://news.google.com/rss/articles/CBMiZkFVX3lxTE1iOEtjQmlEbDNUaEhhZTVLbFM0Mk42TzNucDl5aC1tOG1Qa0JYdHk5V2ZPMVd1cFpFYlZJak1EbW5TQjhMZkw1LV9KR20xRTFETGk2RVhEYXhXRUYzNEJGWGcwMkp4Zw?oc=5) |
| grafa.com | AbbVie ABBV-466 Achieves 40.5% Crohn's Remission | 2026-10-19 09:15 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxNTG14Rk5zeGhEOEl6V2V1Sy12cThCUGFZQkt1cWo1T1QySWNZX2YtWHR2RGpWOENWSW5XTzdNbWhCTzNNUnpfa2tBZU9QbkdiTm9CRk9SVzJucDhkWEwxRWZGUlV5U2gwMGF6MGQyaEl3bEZMOC00LXBkRk9KOVFRb3lLLWE5WUM2VjYtTDFuanI1dU1ZMFE?oc=5) |
| Fierce Biotech | AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial | 2026-10-19 09:15 | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxNLVhXd3hYZ3JON05ENHJzdFpKdlI2V1dMUmhpU3lKTnhiMXBZYng2LS1MVWtMVzFRbTBwU1dYS1dfLWNYczhVRFJ4blhkcFRTMFg3bWZnczM1dWI3VlphVHRINWxzbE55T2lFM0tDaVhQYml3MWpJUnM0amI3MTlIdTlaWk8wUGtWdHl5WG5ublFPVGI3UnJnMG1pbWlHYTRsZ09z?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-19/abbvie-s-next-gen-crohn-s-disease-combo-beats-skyrizi-in-phase-2-trial*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*